Abstract | OBJECTIVES: METHODS: We retrospectively evaluated 95 patients according to their rethrombotic status. We registered anticoagulation (OA) status, comorbidities, traditional thrombotic factors, prevalence of aCL ( IgG- IgM), anti-β2GP-I ( IgG- IgM), LA and triple marker positivity (LA, aCL and anti-β2GP-I). RESULTS: Forty-two patients had rethrombosis and 53 were rethrombosis-free. The median follow-up was 4.5 (0.3-26) years. There were no differences in comorbidities and traditional thrombotic factors. Patients with rethrombosis had more frequently LA (62% vs. 40%, p=0.04), were younger (41 vs. 47 years, p=0.01) and received less frequently OA (23% vs. 54%, p=0.002). A logistic regression analysis showed that the OA status (OR 0.17, 95% CI 0.05-0.57, p=0.004) and age (OR 0.94, 95% CI 0.90-0.98, p=0.01) remained significant. Patients who discontinued OA and developed rethrombosis (Group 1, n=32) vs. patients who discontinued OA, but remained rethrombosis-free (Group 2, n=24) were also analysed. We found a higher prevalence of LA and triple marker positivity in Group 1 (67% vs. 31%; OR= 4.5, 95% CI 1.3-14.9, p= 0.01 and 57% vs. 27%; OR 3.6, 95% CI 1.7-12; p=0.03), respectively. Both variables remained associated with rethrombosis when compared with the overall rethrombosis group vs. Group 2 (LA 62% vs. 31%, OR= 3.6 95% CI 1.1-11.2, p=0.03; triple marker 54% vs. 27%; OR 32 95% CI 1.01-10.2, p=0.05). CONCLUSIONS: LA positivity and triple aPL positivity confer a more severe risk of rethrombosis in PAPS patients, irrespective of their anticoagulation status and known conventional risk factors.
|
Authors | Gabriela Hernández-Molina, Grissel Espericueta-Arriola, Antonio R Cabral |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2013 May-Jun
Vol. 31
Issue 3
Pg. 382-8
ISSN: 0392-856X [Print] Italy |
PMID | 23305633
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Anticardiolipin
- Anticoagulants
- Immunoglobulin G
- Immunoglobulin M
- Lupus Coagulation Inhibitor
- beta 2-Glycoprotein I
|
Topics |
- Adult
- Antibodies, Anticardiolipin
(immunology)
- Anticoagulants
(therapeutic use)
- Antiphospholipid Syndrome
(complications, immunology)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G
(immunology)
- Immunoglobulin M
(immunology)
- Kaplan-Meier Estimate
- Lupus Coagulation Inhibitor
(immunology)
- Male
- Middle Aged
- Recurrence
- Retrospective Studies
- Risk Factors
- Thrombosis
(etiology, immunology, prevention & control)
- beta 2-Glycoprotein I
(immunology)
|